Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...

Pfizer is drawing renewed market attention as healthcare strength, pharmaceutical deal activity, and defensive demand reshape ...

Classic Mercedes design meets the 2025 S63 in a visual mashup that draws attention to two very different eras of the same ...

In his Sunday column, Jim Cramer explores the dominance of tech stocks and the upside potential that still remains.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. Today's catalyst is ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...

MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Pandemic-era favorites such as Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) will be under scrutiny after President Donald Trump on Monday urged the companies to justify the success of their COVID-19 ...